We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Partners Seek to Develop New Imagining Agents for Cardiovascular Disease Diagnosis

By HospiMedica International staff writers
Posted on 09 Dec 2013
Partners in a recently signed research agreement will be developing new imaging agents for the noninvasive measurement of blood flow in the heart for the diagnosis of cardiovascular diseases–a sector worth of some two billion USD annually.

Hadasit (Jerusalem, Israel), the technology transfer company of the Hadassah Medical Organization (Jerusalem, Israel) announced the initiation of a three-year license and cooperation agreement with Synektik SA (Warsaw, Poland) to develop new imagining agents for use in PET/CT scans, which will enable the quantitative measurement of blood flow to the heart. More...
The potential agents are expected to enable the clinician to determine the extent of damage resulting from a heart attack, and predict the degree of recovery after the heart attack or bypass surgery.

Research will be conducted at the Hadassah Medical Organization in Jerusalem in cooperation with Synektik's new research and development facility in Warsaw. Development funding of four million USD will be provided by Synektik, which will receive a worldwide license for any newly developed imaging agent and will spearhead further development, clinical trials registration, and commercialization.

Dr. Eyal Mishani, director of the cyclotron and radiochemistry unit of the Hadassah Medical Organization, said, "The funding would facilitate pre-clinical research and development stages and preparation for clinical trials which will be performed jointly with Synektik."

Related Links:

Hadasit
Hadassah Medical Organization
Synektik SA



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Wound Irrigation Solution
Prontosan®
New
Gold Member
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Sphere-9 is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter to be CE marked for ventricular ablation (Photo courtesy of Medtronic)

Dual-Energy Mapping and Ablation Catheter Receives CE Mark for Ventricular Arrhythmias

Ventricular arrhythmias, including ventricular tachycardia and premature ventricular complexes, can be life-threatening and often occur in patients with advanced heart disease. Although catheter ablation... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.